The future of engineered immune cell therapies
Immune cells are being engineered to recognize and respond to disease states, acting as a
“living drug” when transferred into patients. Therapies based on engineered immune cells …
“living drug” when transferred into patients. Therapies based on engineered immune cells …
Prolonged viral suppression with anti-HIV-1 antibody therapy
HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …
effective but requires lifelong drug administration owing to a stable reservoir of latent …
Broadly neutralizing antibodies targeting HIV: Progress and challenges
Anti-HIV broadly neutralizing antibodies (bNAbs) offer a novel approach to treating,
preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer …
preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer …
Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering
The programmed cell death protein 1 (PD‐1) signaling pathway is a major source of
dampened T cell activity in the tumor microenvironment. While clinical approaches to …
dampened T cell activity in the tumor microenvironment. While clinical approaches to …
[HTML][HTML] In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells
K Anthony-Gonda, A Ray, H Su, Y Wang, Y Xiong… - JCI insight, 2022 - ncbi.nlm.nih.gov
HIV-specific chimeric antigen receptor–T cell (CAR T cell) therapies are candidates to
functionally cure HIV infection in people with HIV (PWH) by eliminating reactivated HIV …
functionally cure HIV infection in people with HIV (PWH) by eliminating reactivated HIV …
[HTML][HTML] Next-generation bNAbs for HIV-1 cure strategies
AI Schriek, YLT Aldon, MJ van Gils, SW de Taeye - Antiviral research, 2024 - Elsevier
Despite the ability to suppress viral replication using anti-retroviral therapy (ART), HIV-1
remains a global public health problem. Curative strategies for HIV-1 have to target and …
remains a global public health problem. Curative strategies for HIV-1 have to target and …
Advancements in Cell-Based Therapies for HIV Cure
Y Matsui, Y Miura - Cells, 2023 - mdpi.com
The treatment of human immunodeficiency virus (HIV-1) has evolved since the
establishment of combination antiretroviral therapy (ART) in the 1990s, providing HIV …
establishment of combination antiretroviral therapy (ART) in the 1990s, providing HIV …
Dopamine Signaling Promotes Tissue-Resident Memory Differentiation of CD8+ T Cells and Antitumor Immunity
Tissue-resident memory CD8+ T (TRM) cells have been associated with robust protective
antitumor immune responses and improved prognosis of patients with cancer. Therefore …
antitumor immune responses and improved prognosis of patients with cancer. Therefore …
Opportunities for CAR-T cell immunotherapy in HIV cure
G Campos-Gonzalez, J Martinez-Picado… - Viruses, 2023 - mdpi.com
Chimeric antigen receptor (CAR) technology is having a huge impact in the blood
malignancy field and is becoming a well-established therapy for many types of leukaemia. In …
malignancy field and is becoming a well-established therapy for many types of leukaemia. In …
Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
FH Rothemejer, NP Lauritsen, AK Juhl… - Viruses, 2023 - mdpi.com
Adoptive immunotherapy using chimeric antigen receptor (CAR) T cells has been highly
successful in treating B cell malignancies and holds great potential as a curative strategy for …
successful in treating B cell malignancies and holds great potential as a curative strategy for …